EGFR amplification and lack of activating mutations in metaplastic breast carcinomas

Journal of Pathology

Volumn 209, Issue 4, 2006, Pages 445-453

  Reis Filho, Jorge S ^a,b,c   Pinheiro, C ^c   Lambros, M B K ^a   Milanezi, F ^b,c   Carvalho, S ^b   Savage, K ^a   Simpson, P T ^d   Jones, C ^a   Swift, S ^a   Mackay, A ^a   Reis, R M ^c   Hornick, J L ^e   Pereira, E M ^f   Baltazar, F ^c   Fletcher, C D M ^e   Ashworth, A ^a   Lakhani, S R ^d   Schmitt, F C ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b University of Porto   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Laboratory of Clinical Pathology Salomão and Zoppi   (Brazil)

Author keywords

Breast cancer; Chromogenic in situ hybridization; Gene mutation; Immunohistochemistry; Microarrays

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CHROMOSOME 7P; CHROMOSOME ARM; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EXON; GENE AMPLIFICATION; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENE OVEREXPRESSION; GENOME; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; METAPLASIA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

BREAST NEOPLASMS; CARCINOMA; CARCINOMA, SQUAMOUS CELL; DATA INTERPRETATION, STATISTICAL; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; GENOME; HUMANS; IN SITU HYBRIDIZATION; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SARCOMA; SURVIVAL RATE;

EID: 33746911642     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2004     Document Type: Article

References (57)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Rev Cancer 2005;5:341-354.
2. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-2459.
3. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004;63:314-322.
4. Marquez A, Wu R, Zhao J, Tao J, Shi Z. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 2004;13:1-8.
5. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005;23:3235-3242.
6. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655.
7. Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y, et al. Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 2003;1:438-445.
8. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005;18:1027-1033.
9. Corzo C, Tusquets I, Salido M, Corominas JM, Bellet M, Suarez M, et al. Characterization of HER1 (c-erbB1) status in locally advanced breast cancer using fluorescence in situ hybridization and immunohistochemistry. Tumour Biol 2005;26:25-30.
10. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-8540.
11. Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, et al. Metaplastic breast carcinomas show EGFR, but not HER2, gene amplification and overexpression: immunohisto-chemical and chromogenic in situ hybridisation analysis. Breast Cancer Res 2005;7:R1028-R1035.
12. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-3234.
13. Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;in press.
14. Leibl S, Gogg-Kammerer M, Sommersacher A, Denk H, Moinfar F. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: Immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 2005;29:347-353.
15. Dunne B, Lee AH, Pinder SE, Bell JA, Ellis IO. An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol 2003;34:1009-1015.
16. Popnikolov NK, Ayala AG, Graves K, Gatalica Z. Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas. Am J Clin Pathol 2003;120:161-167.
17. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, et al. Distribution and significance of nerve growth factor receptor (NGFR/ p75(NTR)) in normal, benign and malignant breast tissue. Mod Pathol 2006;19:307-319.
18. Reis-Filho JS, Milanezi F, Paredes J, Silva P, Pereira EM, Maeda SA, et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 2003;11:1-8.
19. Carter MR, Hornick JL, Lester S, Fletcher CDM. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immumohistochemical analysis of 29 cases. Am J Surg Pathol 2006;30:300-309.
20. Leibl S, Moinfar F. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol 2005;58:700-704.
21. Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, et al. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. Int J Surg Pathol 2005;13:319-327.
22. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 1990;21:1142-1150.
23. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 1990;65:272-276.
24. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 1989;64:1490-1499.
25. Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol 1989;20:732-740.
26. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 1989;20:628-635.
27. Huvos AG, Lucas JC Jr, Foote FW Jr. Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med 1973;73:1078-1082.
28. Oberman HA. Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol 1987;11:918-929.
29. Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 2005;207:1-13.
30. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004;20:3413-3422.
31. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-271.
32. Reis-Filho JS, Schmitt FC. p63 expression in sarcomatoid/metaplastic carcinomas of the breast. Histopathology 2003;42:94-95.
33. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
34. Enghardt MH, Hale JH. An epithelial and spindle cell breast tumour of myoepithelial origin. An immunohistochemical and ultrastructural study. Virchows Arch A Pathol Anat Histopathol 1989;416:177-184.
35. Harb JM, Komorowski RA, Vitali CM. Metaplastic breast carcinoma invading chest wall. Ultrastruct Pathol 1995;19:439-443.
36. Rosai J. Rosai and Ackerman's Surgical Pathology (9th edn). Mosby: Edinburgh, 2003.
37. Greenfield JJ, High S. The Sec61 complex is located in both the ER and the ER-Golgi intermediate compartment. J Cell Sci 1999;112:1477-1486.
38. Eley GD, Reiter JL, Pandita A, Park S, Jenkins RB, Maihle NJ, et al. A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma. Neuro-oncol 2002;4:86-94.
39. Park S, James CD. Lanthionine synthetase component C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism. Cancer Res 2003;63:723-727.
40. Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y, Minna JD, et al. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 2005;36:1127-1134.
41. Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena RM, et al. Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer 2005;92:1922-1926.
42. Kersting C, Tidow N, Schmidt H, Liedtke C, Neumann J, Boecker W, et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 2004;84:582-587.
43. Santini D, Ceccarelli C, Tardio ML, Taffurelli M, Marrano D. Immunocytochemical expression of epidermal growth factor receptor in myoepithelial cells of the breast. Appl Immunohistochem Mol Morphol 2002;10:29-33.
44. Tsuda H, Morita D, Kimura M, Shinto E, Ohtsuka Y, Matsubara O, et al. Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci 2005;96:48-53.
45. Shien T, Tashiro T, Omatsu M, Masuda T, Furuta K, Sato N, et al. Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation. J Clin Pathol 2005;58:1299-1304.
46. Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP, et al. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 2005;24:3177-3186.
47. Berquin IM, Dziubinski ML, Nolan GP, Ethier SP. A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin. Oncogene 2001;20:4019-4028.
48. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 1992;89:2965-2969.
49. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000;60:3081-3087.
50. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995;55:5536-5539.
51. Rae JM, Scheys JO, Clark KM, Chadwick RB, Kiefer MC, Lippman ME. EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat 2004;87:87-95.
52. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-8092.
53. Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, Stokoe D. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 2005;4:1369-1372.
54. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res 2005;65:10524-10535.
55. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-1141.
56. Cappuzzo F. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? J Natl Cancer Inst 2005;97:868-869.
57. Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005;20:1005-1015.